S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

ABSTRACT: RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride. PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.

DISEASE(S): Dermatologic Complications,Lung Cancer,Colorectal Cancer,Colorectal Neoplasms,Therapy-related Toxicity,Lung Neoplasms

PROVIDER: 2111477 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR